<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39460317</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>28</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2076-393X</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>10</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>08</Day></PubDate></JournalIssue><Title>Vaccines</Title><ISOAbbreviation>Vaccines (Basel)</ISOAbbreviation></Journal><ArticleTitle>Clustering Analysis Identified Distinct Clinical Phenotypes among Hemodialysis Patients in Their Immunological Response to the BNT162b2 mRNA Vaccine against SARS-CoV-2.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1150</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/vaccines12101150</ELocationID><Abstract><AbstractText><b>Background:</b> The 2019 coronavirus disease (COVID-19) pandemic induced a major health crisis worldwide, notably among end-stage kidney disease (ESKD) patients. Vaccination against SARS-CoV-2, especially with messenger RNA (mRNA) vaccines, is highly effective and reduces hospitalization and mortality in both the general and ESKD populations. Age and previous COVID-19 infection have been identified as major determinants of the vaccine response in both the general population and ESKD patients. <b>Methods:</b> To determine the specific phenotype of ESKD patients in relation to their vaccine response, a clustering approach was used in a cohort of 117 fully vaccinated patients. <b>Results:</b> Clustering revealed three distinct clinical phenotypes among hemodialysis patients in terms of immunological response. Two clusters, consisting of either women with a long dialysis history or male subjects with diabetes with a moderate history of dialysis, exhibited low levels of IgG anti-spike antibodies. The third cluster consisted of non-diabetic middle-aged men with a moderate dialysis vintage and a very good serological response to vaccination. <b>Conclusions:</b> These vaccinal phenotypes of dialysis patients are easily identifiable in current practice, allowing for differential serological follow-up and tailored booster SARS-CoV-2 vaccination.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rostoker</LastName><ForeName>Guy</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0002-4383-3825</Identifier><AffiliationInfo><Affiliation>Department of Nephrology and Dialysis, Claude Galien Private Hospital-Ramsay Health Care, 91480 Quincy-sous-Sénart, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Collège de Médecine des Hôpitaux de Paris, 75610 Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rouanet</LastName><ForeName>Stéphanie</ForeName><Initials>S</Initials><Identifier Source="ORCID">0009-0003-5812-3599</Identifier><AffiliationInfo><Affiliation>StatEthic, 92300 Levallois-Perret, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Griuncelli</LastName><ForeName>Mireille</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Nephrology and Dialysis, Claude Galien Private Hospital-Ramsay Health Care, 91480 Quincy-sous-Sénart, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Loridon</LastName><ForeName>Christelle</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Nephrology and Dialysis, Claude Galien Private Hospital-Ramsay Health Care, 91480 Quincy-sous-Sénart, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boulahia</LastName><ForeName>Ghada</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Nephrology and Dialysis, Claude Galien Private Hospital-Ramsay Health Care, 91480 Quincy-sous-Sénart, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gagnon</LastName><ForeName>Luc</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>IQVIA Laboratories Vaccines, Laval, QC H7V 3S8, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>This research was funded by Ramsay Health Cooperation Group for Education and Research (GCS Ramsay Santé, No. COS-RGDS-2021-06-075). Ramsay Santé supported this study for Clini-cal samples analysis (with the company Nexelis/Q2 Solutions), proofreading in</GrantID><Agency>Ramsay Santé</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Vaccines (Basel)</MedlineTA><NlmUniqueID>101629355</NlmUniqueID><ISSNLinking>2076-393X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">IgG anti-spike antibodies</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">clustering</Keyword><Keyword MajorTopicYN="N">dialysis</Keyword><Keyword MajorTopicYN="N">mRNA vaccination</Keyword></KeywordList><CoiStatement>G.R. reports receiving consultancy fees from Astellas (board on Roxadustat, 2019–2021, 2023), GlaxoSmithKline (board on Daprodustat, 2022–2023), Vifor (board on Difelikefalin, 2021–2023), and reports research funding for scientific presentations from Amgen, Astellas, Baxter, Hemotech, Gambro Hospal, Nipro, Physidia, and Theradial. He also reports receiving honoraria from Amgen, Astellas, GlaxoSmithKline, Roche, Sanofi, and Vifor, and is on the speakers’ bureau for Astellas and Baxter. G.R. is employed as a nephrologist by SELARL de Néphrologie et de Dialyse des Drs Rostoker et Associés (a limited liability company for non-commercial services), where he serves as the manager. SR is a statistician employed by the company StatEthic in Levallois-Perret, of which she is the founder. G.B. is a collaborator of the SELARL de Néphrologie et de Dialyse des Drs Rostoker et Associés at the private hospital Claude Galien in Quincy-sous-Sénart. M.G. and C.L. are employed by SELARL de Néphrologie et de Dialyse des Drs Rostoker et Associés at the Claude Galien private hospital in Quincy-sous-Sénart. L.G. is a PhD in Microbiology and Immunology and he is the Global Head of Vaccine Sciences at IQVIA Laboratories in Laval, Canada. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>19</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>19</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>1</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>8</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39460317</ArticleId><ArticleId IdType="pmc">PMC11511590</ArticleId><ArticleId IdType="doi">10.3390/vaccines12101150</ArticleId><ArticleId IdType="pii">vaccines12101150</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>El Karoui K., De Vriese A.S. COVID-19 in dialysis: Clinical impact, immune response, prevention and treatment. Kidney Int. 2022;101:883–894. doi: 10.1016/j.kint.2022.01.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.kint.2022.01.022</ArticleId><ArticleId IdType="pmc">PMC8842412</ArticleId><ArticleId IdType="pubmed">35176326</ArticleId></ArticleIdList></Reference><Reference><Citation>Barouch D.H. COVID-19 vaccines—Immunity, Variants, Boosters. N. Engl. J. Med. 2022;387:1011–1020. doi: 10.1056/NEJMra2206573.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra2206573</ArticleId><ArticleId IdType="pmc">PMC9454645</ArticleId><ArticleId IdType="pubmed">36044620</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashby D.R., Caplin B., Corbett R.W., Asgari E., Kumar N., Sarnowski A., Hull R., Makanjuola D., Cole N., Chan J., et al. Severity of COVID-19 after vaccination among hemodialysis patients: An observational cohort study. Clin. J. Am. Soc. Nephrol. 2022;17:843–850. doi: 10.2215/CJN.16621221.</Citation><ArticleIdList><ArticleId IdType="doi">10.2215/CJN.16621221</ArticleId><ArticleId IdType="pmc">PMC9269655</ArticleId><ArticleId IdType="pubmed">35649718</ArticleId></ArticleIdList></Reference><Reference><Citation>Mink S., Fraunberger P. Anti-SARS-CoV-2 antibody testing: Role and indications. J. Clin. Med. 2023;12:7575. doi: 10.3390/jcm12247575.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm12247575</ArticleId><ArticleId IdType="pmc">PMC10744049</ArticleId><ArticleId IdType="pubmed">38137643</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan L., Fuca N., Zeldis E., Campbell K.N., Shaikh A. Antibody Response to mRNA-1273 SARS-CoV-2 Vaccine in hemodialysis Patients with and without Prior COVID-19. Clin. J. Am. Soc. Med. 2021;16:1258–1260. doi: 10.2215/CJN.04080321.</Citation><ArticleIdList><ArticleId IdType="doi">10.2215/CJN.04080321</ArticleId><ArticleId IdType="pmc">PMC8455039</ArticleId><ArticleId IdType="pubmed">34031182</ArticleId></ArticleIdList></Reference><Reference><Citation>Guinault D., Bernier M., Delarche A., Neuville S., Milioto O., Molinari N., Dahan P. Immunogenicity of the BNT162b2 vaccine in patients undergoing maintenance hemodialysis is associated with medical conditions. Nephron. 2022;146:553–558. doi: 10.1159/000524292.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000524292</ArticleId><ArticleId IdType="pubmed">35477156</ArticleId></ArticleIdList></Reference><Reference><Citation>Li T., Gandra S., Reske K.A., Olsen M.A., Bommarito S., Miller C., Hock K.G., Ballman C.A., Su C., Le Dang N. Predictors of humoral response to SARS-CoV-2 mRNA vaccine BNT162b2 in patients receiving maintenance dialysis. Antimicrob. Steward. Healthc. Epidemiol. 2022;2:e48. doi: 10.1017/ash.2022.31.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/ash.2022.31</ArticleId><ArticleId IdType="pmc">PMC9615013</ArticleId><ArticleId IdType="pubmed">36310813</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho K., Park S., Kim E.K., Koyanagi A., Jacob L., Yon D.K., Lee S.W., Kim M.S., Radua J., Elena D., et al. Immunogenicity of COVID-19 vaccines in patients with diverse health conditions: A comprehensive systematic review. J. Med. Virol. 2022;94:4144–4155. doi: 10.1002/jmv.27828.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.27828</ArticleId><ArticleId IdType="pmc">PMC9347877</ArticleId><ArticleId IdType="pubmed">35567325</ArticleId></ArticleIdList></Reference><Reference><Citation>Pellegrino R., Pellino G., Selvaggi L., Selvaggi F., Federico A., Romano M., Gravina A.G. BNT162b2 mRNA COVID-19 vaccine is safe in a setting of patients on biologic therapy with inflammatory bowel diseases: A monocentric real-life study. Expert Rev. Clin. Pharmacol. 2022;15:1243–1252. doi: 10.1080/17512433.2022.2120466.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17512433.2022.2120466</ArticleId><ArticleId IdType="pubmed">36047032</ArticleId></ArticleIdList></Reference><Reference><Citation>Reynolds A.P., Richards G., De la Iglesia B., Rayward-Smith V.J. Clustering Rules: A Comparison of Partitioning and Hierarchical Clustering Algorithms. J. Math. Model. Algorithms. 2006;5:475–504. doi: 10.1007/s10852-005-9022-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10852-005-9022-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Gower J.C. A general coefficient of similarity and some of its properties. Biometrics. 1971;27:857–871. doi: 10.2307/2528823.</Citation><ArticleIdList><ArticleId IdType="doi">10.2307/2528823</ArticleId></ArticleIdList></Reference><Reference><Citation>Rousseeuw P.J. Silhouettes: A graphical aid to the interpretation and validation of cluster analysis. J. Comput. Appl. Math. 1987;20:53–65. doi: 10.1016/0377-0427(87)90125-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0377-0427(87)90125-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossi M., Pessolano G., Gambaro G. What has vaccination against COVID-19 in CKD taught us? J. Nephrol. 2023;36:1257–1266. doi: 10.1007/s40620-023-01640-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40620-023-01640-w</ArticleId><ArticleId IdType="pmc">PMC10157569</ArticleId><ArticleId IdType="pubmed">37140817</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi H., Eguchi J., Watanabe M., Nakayama M., Wada J. Reduced immunogenicity of COVID-19 vaccine in obese patients with type 2 diabetes: A cross-sectional study. Acta Med. Okayama. 2024;78:185–191. doi: 10.18926/AMO/66927.</Citation><ArticleIdList><ArticleId IdType="doi">10.18926/AMO/66927</ArticleId><ArticleId IdType="pubmed">38688836</ArticleId></ArticleIdList></Reference><Reference><Citation>Vena W., Pigni S., Betella N., Navarra A., Mirani M., Mazziotti G., Lania A.G. Covid-19 vaccines and blood glucose control: Friend or Foe? Hum. Vaccines Immunother. 2024;20:236306. doi: 10.1080/21645515.2024.2363068.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2024.2363068</ArticleId><ArticleId IdType="pmc">PMC11178329</ArticleId><ArticleId IdType="pubmed">38860457</ArticleId></ArticleIdList></Reference><Reference><Citation>Steiger S., Rossaint J., Zarbock A., Anders H.J. Secondary immunodeficiency related to kidney disease (SIDKD)-Definition, unmet need, and mechanisms. J. Am. Soc. Nephrol. 2022;33:259–278. doi: 10.1681/ASN.2021091257.</Citation><ArticleIdList><ArticleId IdType="doi">10.1681/ASN.2021091257</ArticleId><ArticleId IdType="pmc">PMC8819985</ArticleId><ArticleId IdType="pubmed">34907031</ArticleId></ArticleIdList></Reference><Reference><Citation>Yau K., Chan C.T., Abe K.T., Jiang Y., Atiquzzaman M., Mullin S.I., Shadowitz E., Liu L., Kostadinovic E., Sukovic T., et al. Difference in mRNA-1273 (Moderna) and BNT162b2 (Pfizer-BioNTech) SARS-CoV-2 vaccine immunogenicity among patients undergoing dialysis. CMAJ. 2022;28:E297–E305. doi: 10.1503/cmaj.211881.</Citation><ArticleIdList><ArticleId IdType="doi">10.1503/cmaj.211881</ArticleId><ArticleId IdType="pmc">PMC9053976</ArticleId><ArticleId IdType="pubmed">35115375</ArticleId></ArticleIdList></Reference><Reference><Citation>Yau K., Tam P., Chan C.T., Hu Q., Qi F., Abe K.T., Kurtesi A., Jiang Y., Estrada-Codecido J., Brown T., et al. BNT162b2 versus mRNA-1273 third dose COVID-19 vaccine in patients with CKD and maintenance dialysis patients. Clin. J. Am. Soc. Nephrol. 2024;19:85–97. doi: 10.2215/CJN.0000000000000328.</Citation><ArticleIdList><ArticleId IdType="doi">10.2215/CJN.0000000000000328</ArticleId><ArticleId IdType="pmc">PMC10843183</ArticleId><ArticleId IdType="pubmed">37847518</ArticleId></ArticleIdList></Reference><Reference><Citation>Debelle F., Phuong Nguyen V.T., Boitquin L., Guillen-Anaya M.A., Gankam F., Declèves A.E., CoviDial Study Group Monitoring strategy of COVID-19 vaccination in dialysis patients based on a multiplex immunodot method: The CoviDial Study. Semin. Dial. 2024;37:145–152. doi: 10.1111/sdi.13175.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/sdi.13175</ArticleId><ArticleId IdType="pubmed">37718617</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>